Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Application of beneficial microorganisms as probiotics targets a broad range of intended uses, from maintaining health and supporting normal bodily functions to curing and preventing diseases. Currently, three main regulatory fields of probiotic products can be defined depending on their intended use: the more similar probiotic foods and probiotic dietary supplements, and live biotherapeutic products. However, it is not always straightforward to classify a probiotic product into one of these categories. The regulatory nuances of developing, manufacturing, investigating and applying each category of probiotic products are not universal, and not always apparent to those unfamiliar with the various global probiotic regulatory guidelines. Various global markets can be significantly different regarding legislation, possible claims, market value and quality requirements for the development and commercialization of probiotic products. Furthermore, different probiotic product categories are also linked with variable costs at different stages of product development. This review outlines the current landscape comparing probiotic foods, probiotic dietary supplements, and live biotherapeutics as probiotic products from a regulatory lens, focusing on product development, manufacturing and production, and clinical research agenda. The aim is to inform and promote a better understanding among stakeholders by outlining the expectations and performance for each probiotic product category, depending on their intended use and targeted geographical region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The European Union lacks dedicated probiotic legislation, though health claims are regulated. Japan, Brazil, and Canada offer more structured frameworks that mandate safety and efficacy evidence.39”
From Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing and in vitro assessment (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Probiotics marketed as foods or dietary supplements are subject to food and consumer product safety legislation. In contrast, live biotherapeutic products, intended to treat or prevent diseases, are regulated as biological medicinal products. This means that they must undergo rigorous safety, efficacy, and quality testing similar to that applied to pharmaceuticals [29,30].”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Regulatory challenges affecting the commercialization of probiotics include the lack of harmonization of regulatory requirements, which can vary by region (e.g., as with drugs or dietary supplements), leading to confusion in interpreting requirements. Efficacy and safety standards also vary, increasing costs and complicating worldwide regulatory compliance, which in turn leads to differences in”
From Current Concepts in Probiotic Safety and Efficacy (2026) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“…from synthesis to clinical testing) for drugs is expensive and time-consuming, as it has been reported to average a considerable 31.7 months with inferred out-of-pocket costs of 430 million USD based on 1990– 2013 data on 106 new drugs from 10 biopharmaceutical companies (DiMasi et al., 2016).”
BackgroundInfluentialZheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., O’Toole, P. W., Pot, B., Vandamme, P., Walter, J., et al. (2020) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijsem.0.004107 · Cited by 3,313
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00390-5 · Cited by 937
Probiotics for preventing acute upper respiratory tract infections
Hao, Q., Dong, B. R., & Wu, T. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006895.pub3 · Cited by 569
Criteria to Qualify Microorganisms as “Probiotic” in Foods and Dietary Supplements
Binda, S., Hill, C., Johansen, E., Obis, D., Pot, B., Sanders, M. E., Tremblay, A., & Ouwehand, A. C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01662 · Cited by 519
Self-citationEmerging issues in probiotic safety: 2023 perspectives
Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185034 · Cited by 481
Self-citationThe Production and Delivery of Probiotics: A Review of a Practical Approach
Fenster, K., Freeburg, B., Hollard, C., Wong, C., Rønhave Laursen, R., & Ouwehand, A. C. (2019) · Microorganisms · doi:10.3390/microorganisms7030083 · Cited by 405
Self-citation
Research works printed but not linked: 18
- 2023, Current Good Manufacturing Practices (CGMPs).
- Chieffi, 2022, Legislation of probiotic foods and supplements. Probiotics for human nutrition in health and disease.
- 1994, S.784 - Dietary Supplement Health and Education Act of 1994. 103rd Congress (1993-1994).
- 2007, Corrigendum to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods., Official J. Eur. Union, 12
- 2017, Hazard Analysis and Critical Control Point (HACCP).
- 2022, H.R.2617 - Consolidated Appropriations Act, 2023.
- 2023, Reimbursement of Pharmaceuticals.
- 2023, Probiotics.
- 2023, Do you know what probiotics are?
- 2021, Explained: The US E-commerce probiotic supplements market.
- 2023, Hazard Analysis and Critical Control Points (HACCP) understanding HACCP food safety standards.
- Paraskevakos, 2020, Global overview for probiotics: trends, markets, and harmonization. Regulatory Focus.
- 2019, Live biotherapeutic products for human use 3053 monograph., Eur. Pharmacopoeia, 9, 6522
- 2001, Grants and contracts for development of drugs for rare diseases and conditions.
- 2016, Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information. Guidance for Industry.
- 2021, Facts About the Current Good Manufacturing Practices (CGMPs).
- Authorized health claims that meet the Significant Scientific Agreement (SSA) Standard.
- Investigational New Drug (IND) application.
Cited by
Abouelela, M. E., & Helmy, Y. A. (2024) · Microorganisms · doi:10.3390/microorganisms12030430 · Cited by 238
“The situation in the EU is not currently harmonized, with different member states taking different approaches to the regulation of probiotics [47].”
BackgroundEncapsulation method of probiotic embedded delivery system and its application in food
Bu, W., McClements, D. J., Zhang, Z., Zhang, R., Jin, Z., & Chen, L. (2024) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2024.110625 · Cited by 87
Progress in Probiotic Science: Prospects of Functional Probiotic‐Based Foods and Beverages
Manan, M. A. (2025) · International Journal of Food Science · doi:10.1155/ijfo/5567567 · Cited by 88
“Proving the e ffi cacy of these products through scienti fi c evidence and clinical trials is often intricate and time-consuming [18, 314].”
InfluentialRecent advances in prebiotics: Classification, mechanisms, and health applications
Ali, S., Hamayun, M., Siraj, M., Khan, S. A., Kim, H., & Lee, B. (2025) · Future Foods · doi:10.1016/j.fufo.2025.100680 · Cited by 78
Sachdeva, A., Tomar, T., Malik, T., Bains, A., & Karnwal, A. (2025) · Frontiers in Sustainable Food Systems · doi:10.3389/fsufs.2024.1523678 · Cited by 84
Metadata
- Authors
- Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., & Ouwehand, A. C.
- Affiliations
- University of Antwerp (BE)
- Fonterra (New Zealand) (NZ)
- AgroParisTech (FR)
- Probiotical (Italy) (IT)
- Corresponding author
- Spacova, Irina
- Ouwehand, Arthur C.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2023-12-19
- Volume
- 14
- Issue
- 3
- Pages
- 1272754-1272754
- ISSN
- 1664-302X (ISSN-L)
- PMC
- PMC10770255
- OpenAlex
- W4389938247
- Cited by
- 129
- References
- 50
- Citations by year
- 2026: 68 · 2025: 47 · 2024: 14
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fonds Wetenschappelijk Onderzoek (1277222N)
- Vlaamse regering
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Agricultural and Biological Sciences › Food Science › Agricultural safety and regulations
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Consumer Attitudes and Food Labeling
- Keywords
- probiotics, probiotic foods, live biotherapeutic products, probiotic regulation, regulatory guidelines, product development, clinical research, health claims, commercialization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. https://app.cochat.ai/papers/10.3389/fmicb.2023.1272754
- The paper
- Spacova, I., Binda, S., ter Haar, J. A., Henoud, S., Legrain-Raspaud, S., Dekker, J., Espadaler-Mazo, J., Langella, P., Martín, R., Pane, M., & Ouwehand, A. C. (2023). Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1272754
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.